- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients - - Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations - - Strengthened financial position with support from largest shareholder - BERGEN, Norway, Nov. 15, 2022...